Entasis Therapeutics to Participate in H.C. Wainwright BioConnect 2022
H.C. Wainwright BioConnect 2022
Format: On-demand investor presentation beginning on
Entasis is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including post Phase 3 sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0462 (targeting multiple Gram-negative pathogens including Pseudomonas aeruginosa) and ETX0282CPDP (targeting Enterobacteriaceae infections). For more information, visit www.entasistx.com.
|Company Contact||Investor Contact|
|(781) 810-0114||(929) 469-3859|
|(215) 315 3143|
Source: Entasis Therapeutics Holdings Inc.